Ascendis Pharma A/S (ASND) Competitors $207.12 -1.59 (-0.76%) Closing price 04:00 PM EasternExtended Trading$206.46 -0.66 (-0.32%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASND vs. ARGX, TAK, ONC, INSM, BNTX, TEVA, GMAB, SMMT, VTRS, and RDYShould you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Ascendis Pharma A/S vs. Its Competitors argenex Takeda Pharmaceutical BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S (NASDAQ:ASND) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends. Do institutionals and insiders believe in ASND or ARGX? 60.3% of argenex shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer ASND or ARGX? In the previous week, argenex had 24 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 36 mentions for argenex and 12 mentions for Ascendis Pharma A/S. argenex's average media sentiment score of 0.77 beat Ascendis Pharma A/S's score of 0.61 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive argenex 16 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, ASND or ARGX? argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M32.47-$409.12M-$5.16-40.14argenex$2.25B22.16$833.04M$19.5041.83 Is ASND or ARGX more profitable? argenex has a net margin of 40.98% compared to Ascendis Pharma A/S's net margin of -54.94%. argenex's return on equity of 21.06% beat Ascendis Pharma A/S's return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% argenex 40.98%21.06%18.25% Which has more risk & volatility, ASND or ARGX? Ascendis Pharma A/S has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Do analysts prefer ASND or ARGX? Ascendis Pharma A/S presently has a consensus price target of $248.29, indicating a potential upside of 19.88%. argenex has a consensus price target of $817.53, indicating a potential upside of 0.23%. Given Ascendis Pharma A/S's higher possible upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than argenex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.88argenex 0 Sell rating(s) 2 Hold rating(s) 20 Buy rating(s) 2 Strong Buy rating(s) 3.00 Summaryargenex beats Ascendis Pharma A/S on 14 of the 17 factors compared between the two stocks. Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASND vs. The Competition Export to ExcelMetricAscendis Pharma A/SMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.88B$3.38B$6.11B$10.46BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-40.1422.7785.3627.36Price / Sales32.47482.84606.87135.08Price / CashN/A46.7037.4661.86Price / Book-110.1710.5512.426.81Net Income-$409.12M-$52.58M$3.32B$276.80M7 Day Performance-1.43%1.09%1.01%0.27%1 Month Performance6.42%16.09%10.75%8.31%1 Year Performance62.70%18.41%76.20%35.60% Ascendis Pharma A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASNDAscendis Pharma A/S3.1864 of 5 stars$207.12-0.8%$248.29+19.9%+62.5%$12.88B$393.54M-40.141,017News CoverageAnalyst ForecastAnalyst RevisionARGXargenex3.7213 of 5 stars$787.94-1.5%$802.90+1.9%+49.6%$48.96B$3.05B40.411,599Trending NewsAnalyst ForecastAnalyst RevisionTAKTakeda Pharmaceutical2.5802 of 5 stars$14.56-0.3%N/A-3.8%$46.46B$30.09B48.5347,455News CoverageAnalyst ForecastONCBeOne Medicines1.8611 of 5 stars$344.53+0.2%$336.30-2.4%N/A$37.69B$3.81B-199.1511,000INSMInsmed2.9598 of 5 stars$158.28+0.7%$149.06-5.8%+114.9%$33.22B$363.71M-27.721,271Analyst ForecastBNTXBioNTech2.1698 of 5 stars$105.16-0.3%$134.56+28.0%-14.6%$25.36B$2.98B-65.726,772Analyst ForecastTEVATeva Pharmaceutical Industries3.2903 of 5 stars$19.99-0.1%$25.57+27.9%+16.7%$22.95B$16.54B-124.9436,830GMABGenmab A/S4.1944 of 5 stars$33.31-0.7%$40.80+22.5%+38.4%$21.55B$3.12B16.742,682Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeSMMTSummit Therapeutics2.9901 of 5 stars$22.15+3.4%$31.29+41.2%+7.4%$15.92B$700K-21.93110Analyst UpgradeGap UpVTRSViatris2.3173 of 5 stars$10.13-0.6%$10.40+2.7%-12.8%$11.88B$14.74B-3.4932,000News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories2.7077 of 5 stars$14.12-0.3%$16.95+20.0%-11.6%$11.82B$3.81B21.3927,811News CoveragePositive News Related Companies and Tools Related Companies ARGX Competitors TAK Competitors ONC Competitors INSM Competitors BNTX Competitors TEVA Competitors GMAB Competitors SMMT Competitors VTRS Competitors RDY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASND) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
